5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 Purity >99.0% (HPLC) Palbociclib Intermediate Factory

Short Description:

5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine

CAS: 733039-20-8

Purity: >99.0% (HPLC)

Appearance: White to Off-White Powder

Intermediate of Palbociclib (CAS: 571190-30-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Palbociclib Related Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Chemical Name	5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine
Synonyms	N-(5-Bromo-2-Chloropyrimidin-4-yl)(cyclopentyl)amine; 5-Bromo-2-Chloro-4-(Cyclopentylamino)pyrimidine
CAS Number	733039-20-8
CAT Number	RF-PI1851
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C9H11BrClN3
Molecular Weight	276.56
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Purity / Analysis Method	>99.0% (HPLC)
1 H NMR Spectrum	Consistent With Structure
Loss on Drying	<1.00%
Total Impurities	<1.00%
Test Standard	Enterprise Standard
Usage	Intermediate of Palbociclib (CAS: 571190-30-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine (CAS: 733039-20-8) can be used as an intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib (trade name: Ibrance) is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or Fulvestrant in women with disease progression following endocrine therapy.